StockData
Palvella Therapeutics, Inc. logo

Palvella Therapeutics, Inc. (PVLA) stock

PVLANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$146.58+2.23 (+1.54%)

Close on Nov 18, 2026Market cap $2.11BP/E –Yield –

Palvella Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Palvella Therapeutics's enterprise value was $2.11B on Nov 11, 2026, against $1.08B a year earlier. Over the last 5 years it ranged from -$36.07M to $2.11B, with a median of $38.26M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$2.11B+92.3%
2025Dec 31, 2025$1.10B–
2024Dec 31, 2024-$3.56M–
2023Dec 29, 2023-$29.53M-489.4%
2022Dec 30, 2022$7.58M-94.8%
2021Dec 31, 2021$145.19M+153.3%
2020Dec 31, 2020$57.33M-38.1%
2019Dec 31, 2019$92.60M+1275.1%
2018Dec 31, 2018$6.73M-97.3%
2017Dec 29, 2017$247.60M+933.9%
2016Dec 30, 2016$23.95M-59.3%
2015Dec 31, 2015$58.79M–
2014Dec 31, 2014-$524.43K–

More Palvella Therapeutics figures

See a number that looks wrong?